These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
142 related articles for article (PubMed ID: 23858594)
1. [The efficacy of enzyme replacement therapy in pompe disease and secondary pathology in pompe muscle "excessive autophagy" which is relevant to the therapy resistance]. Fukuda T No To Hattatsu; 2010 Mar; 42(2):114-6. PubMed ID: 23858594 [No Abstract] [Full Text] [Related]
2. Autophagy in skeletal muscle: implications for Pompe disease. Shea L; Raben N Int J Clin Pharmacol Ther; 2009; 47 Suppl 1(Suppl 1):S42-7. PubMed ID: 20040311 [TBL] [Abstract][Full Text] [Related]
3. Pompe Disease: New Developments in an Old Lysosomal Storage Disorder. Meena NK; Raben N Biomolecules; 2020 Sep; 10(9):. PubMed ID: 32962155 [TBL] [Abstract][Full Text] [Related]
4. Aerobic training as an adjunctive therapy to enzyme replacement in Pompe disease. Nilsson MI; Samjoo IA; Hettinga BP; Koeberl DD; Zhang H; Hawke TJ; Nissar AA; Ali T; Brandt L; Ansari MU; Hazari H; Patel N; Amon J; Tarnopolsky MA Mol Genet Metab; 2012 Nov; 107(3):469-79. PubMed ID: 23041258 [TBL] [Abstract][Full Text] [Related]
5. Gene Therapy for Pompe Disease: The Time is now. Colella P; Mingozzi F Hum Gene Ther; 2019 Oct; 30(10):1245-1262. PubMed ID: 31298581 [TBL] [Abstract][Full Text] [Related]
6. Reduction of Autophagic Accumulation in Pompe Disease Mouse Model Following Gene Therapy. McCall AL; Stankov SG; Cowen G; Cloutier D; Zhang Z; Yang L; Clement N; Falk DJ; Byrne BJ Curr Gene Ther; 2019; 19(3):197-207. PubMed ID: 31223086 [TBL] [Abstract][Full Text] [Related]
8. Suppression of autophagy permits successful enzyme replacement therapy in a lysosomal storage disorder--murine Pompe disease. Raben N; Schreiner C; Baum R; Takikita S; Xu S; Xie T; Myerowitz R; Komatsu M; Van der Meulen JH; Nagaraju K; Ralston E; Plotz PH Autophagy; 2010 Nov; 6(8):1078-89. PubMed ID: 20861693 [TBL] [Abstract][Full Text] [Related]
9. Enhanced efficacy of enzyme replacement therapy in Pompe disease through mannose-6-phosphate receptor expression in skeletal muscle. Koeberl DD; Luo X; Sun B; McVie-Wylie A; Dai J; Li S; Banugaria SG; Chen YT; Bali DS Mol Genet Metab; 2011 Jun; 103(2):107-12. PubMed ID: 21397538 [TBL] [Abstract][Full Text] [Related]
10. Pompe Disease and Autophagy: Partners in Crime, or Cause and Consequence? Rodríguez-Arribas M; Pedro JM; Gómez-Sánchez R; Yakhine-Diop SM; Martínez-Chacón G; Uribe-Carretero E; De Castro DC; Casado-Naranjo I; López de Munaín A; Niso-Santano M; Fuentes JM; González-Polo RA Curr Med Chem; 2016; 23(21):2275-85. PubMed ID: 27237817 [TBL] [Abstract][Full Text] [Related]
11. When more is less: excess and deficiency of autophagy coexist in skeletal muscle in Pompe disease. Raben N; Baum R; Schreiner C; Takikita S; Mizushima N; Ralston E; Plotz P Autophagy; 2009 Jan; 5(1):111-3. PubMed ID: 19001870 [TBL] [Abstract][Full Text] [Related]
12. Differential muscular glycogen clearance after enzyme replacement therapy in a mouse model of Pompe disease. Hawes ML; Kennedy W; O'Callaghan MW; Thurberg BL Mol Genet Metab; 2007 Aug; 91(4):343-51. PubMed ID: 17572127 [TBL] [Abstract][Full Text] [Related]
13. Suppression of autophagy in skeletal muscle uncovers the accumulation of ubiquitinated proteins and their potential role in muscle damage in Pompe disease. Raben N; Hill V; Shea L; Takikita S; Baum R; Mizushima N; Ralston E; Plotz P Hum Mol Genet; 2008 Dec; 17(24):3897-908. PubMed ID: 18782848 [TBL] [Abstract][Full Text] [Related]
14. Enzyme replacement therapy in the mouse model of Pompe disease. Raben N; Danon M; Gilbert AL; Dwivedi S; Collins B; Thurberg BL; Mattaliano RJ; Nagaraju K; Plotz PH Mol Genet Metab; 2003; 80(1-2):159-69. PubMed ID: 14567965 [TBL] [Abstract][Full Text] [Related]
15. Murine muscle cell models for Pompe disease and their use in studying therapeutic approaches. Takikita S; Myerowitz R; Zaal K; Raben N; Plotz PH Mol Genet Metab; 2009 Apr; 96(4):208-17. PubMed ID: 19167256 [TBL] [Abstract][Full Text] [Related]
16. Impaired autophagy affects acid α-glucosidase processing and enzyme replacement therapy efficacy in late-onset glycogen storage disease type II. Nascimbeni AC; Fanin M; Tasca E; Angelini C; Sandri M Neuropathol Appl Neurobiol; 2015 Aug; 41(5):672-5. PubMed ID: 25559662 [No Abstract] [Full Text] [Related]
17. Autophagy and lysosomes in Pompe disease. Fukuda T; Roberts A; Ahearn M; Zaal K; Ralston E; Plotz PH; Raben N Autophagy; 2006; 2(4):318-20. PubMed ID: 16874053 [TBL] [Abstract][Full Text] [Related]
18. Akt inactivation induces endoplasmic reticulum stress-independent autophagy in fibroblasts from patients with Pompe disease. Nishiyama Y; Shimada Y; Yokoi T; Kobayashi H; Higuchi T; Eto Y; Ida H; Ohashi T Mol Genet Metab; 2012 Nov; 107(3):490-5. PubMed ID: 23041259 [TBL] [Abstract][Full Text] [Related]
19. Replacing acid alpha-glucosidase in Pompe disease: recombinant and transgenic enzymes are equipotent, but neither completely clears glycogen from type II muscle fibers. Raben N; Fukuda T; Gilbert AL; de Jong D; Thurberg BL; Mattaliano RJ; Meikle P; Hopwood JJ; Nagashima K; Nagaraju K; Plotz PH Mol Ther; 2005 Jan; 11(1):48-56. PubMed ID: 15585405 [TBL] [Abstract][Full Text] [Related]